Toggle Main Menu Toggle Search

Open Access padlockePrints

Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain

Lookup NU author(s): Dr Margaret Piggott, Professor John O'Brien, Dr Sean Paling, Dr John Fenwick, Emeritus Professor Robert Perry, Emeritus Professor Elaine Perry

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


Abstract

Quinuclidinyl benzilate (QNB) and its derivatives are being developed to investigate muscarinic receptor changes in vivo in Alzheimer's disease and dementia with Lewy bodies. This is the first study of [125I]-(R,R)-I-QNB and [125I]-(R,S)-I-QNB binding in vitro in human brain. We have compared the in vitro binding of the muscarinic ligands [3H]pirenzepine and [3H]AF-DX 384, which have selectivity for the M1 and M2/M4 receptor subtypes, respectively, to the binding of [125I]-(R,R)-I-QNB and [125I]-(R,S)-I-QNB. This will provide a guide to the interpretation of in vivo SPET images generated with [123I]-(R,R)-I-QNB and [123I]-(R,S)-I-QNB. Binding was investigated in striatum, globus pallidus, thalamus and cerebellum, and cingulate, insula, temporal and occipital cortical areas, which show different proportions of muscarinic receptor subtypes, in post-mortem brain from normal individuals. M1 receptors are of high density in cortex and striatum and are relatively low in the thalamus and cerebellum, while M4 receptors are mainly expressed in the striatum, and M2 receptors are most evident in the cerebellum and thalamus. [125I]-(R,R)-I-QNB and [125I]-(R,S)-I-QNB density distribution patterns were consistent with binding to both M1 and M4 receptors, with [125I]-(R,R)-I-QNB additionally binding to a non-cholinergic site not displaceable by atropine. This distribution can be exploited by in vivo imaging, developing ligands for both SPET and PET, to reveal muscarinic receptor changes in Alzheimer's disease and dementia with Lewy bodies during the disease process and following cholinergic therapy. © 2002 Elsevier Science B.V. All rights reserved.


Publication metadata

Author(s): Piggott M, Owens J, O'Brien J, Paling S, Wyper D, Fenwick J, Johnson M, Perry R, Perry E

Publication type: Article

Publication status: Published

Journal: Journal of Chemical Neuroanatomy

Year: 2002

Volume: 24

Issue: 3

Pages: 211-223

Print publication date: 01/09/2002

ISSN (print): 0891-0618

ISSN (electronic): 1873-6300

Publisher: Elsevier

URL: http://dx.doi.org/10.1016/S0891-0618(02)00066-2

DOI: 10.1016/S0891-0618(02)00066-2

PubMed id: 12297267


Altmetrics

Altmetrics provided by Altmetric


Actions

Find at Newcastle University icon    Link to this publication


Share